Cardiomyopathy News and Research

RSS

Cardiomyopathy is a group of diseases with primary, usually diffuse, involvement of the myocardium. The myocardial disease is not secondary to ischaemic, valvular, congenital or pericardial disease.

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.

13 May 2010

Clinical Data expands PGxHealth's FAMILION tests to include two new tests to diagnose heart diseases

Clinical Data, Inc., announced today that its PGxHealth division is expanding its FAMILION family of genetic tests to include two new tests to diagnose heart diseases. With the launch of a test for Conduction Disease associated with Dilated Cardiomyopathy and a test for Short QT Syndrome, PGxHealth continues to lead the industry with the most comprehensive menu of genetic tests to diagnose or confirm familial heart diseases.

12 May 2010

Aastrom Biosciences reports third quarter 2010 FY results

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported financial results for its third fiscal quarter ended March 31, 2010, and also announced progress in its late-stage clinical development programs and corporate operations.

11 May 2010

Deficiency of frataxin protein causes Friedreich's ataxia

The defective gene responsible for Friedreich's ataxia was identified over 20 years ago, but so far our ideas of how this gene causes the disease have been merely speculative. It was assumed that, as a result of the mutation, the gene could no longer be transcribed because this stretch of DNA was inaccessible. FMI Group Leader Marc Bühler and his team have now carried out experiments demonstrating that this is not the case and revealing what actually happens in Friedreich's ataxia.

4 May 2010

Researchers use healthy person's complete genome sequence to predict risk for dozens of diseases

For the first time, researchers have used a healthy person's complete genome sequence to predict his risk for dozens of diseases and how he will respond to several common medications. The risk analysis, from the Stanford University School of Medicine, also incorporates more-traditional information such as a patient's age and gender and other clinical measurements.

30 Apr 2010

Renowned cardiologists to discuss latest research on Hypertrophic Cardiomyopathy at HCMA symposium

Hypertrophic Cardiomyopathy (HCM), the genetic disease in which the muscle of the heart thickens in the absence of an apparent cause, is the leading cause of sudden death in children and young adults. HCM accounts for 40 percent of all deaths on athletic playing fields across the U.S.

29 Apr 2010

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).

22 Apr 2010

Broken heart disease affects women in post menopause period

It seems an infarction, but it's not. It's called Tako-Tsubo syndrome, or stress-induced cardiomyopathy, and it's a rare disease which at first used to be confused with the far more common (and dangerous) cardiac infarction. Patients arrive to the emergency room with the characteristic heart attack symptoms: acute pain in the chest, an electrocardiogram with the typical changes and the release of those enzymes associated with the usual heart disease.

9 Apr 2010

Russia's first implant of SynCardia temporary CardioWest Total Artificial Heart performed on 60-year-old female

On March 23, the Bakoulev Scientific Center for Cardiovascular Surgery (BSCCS) in Moscow performed Russia's first implant of the SynCardia temporary CardioWest™ Total Artificial Heart. The patient, a 60-year-old female suffering from biventricular heart failure, is the world's 850th recipient of the Total Artificial Heart.

9 Apr 2010

HCM: Questions to ask

While a jury awarded Tony and Angela Key, $1.6 million following a malpractice trial in the death of their 22-year-old son, Antwoine, a basketball player for Eastern Connecticut State University who collapsed and died during a game in 2005, it is a small measure of solace when a young life is cut short, particularly when the cause - hypertrophic cardiomyopathy (HCM) - could have been treated, had it been properly diagnosed.

3 Apr 2010

Aastrom Biosciences' RESTORE-CLI trial: Final patient treated

Aastrom Biosciences, Inc., a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported that the final patient has been treated in the company's ongoing multi-center, randomized, double-blind, placebo-controlled U.S. Phase 2b clinical trial designated RESTORE-CLI. This patient received intramuscular injections of either Aastrom's tissue repair cells (TRCs) or electrolyte solution (placebo) for the treatment of critical limb ischemia (CLI), the end-stage of peripheral arterial disease.

26 Mar 2010

Sports Injuries: Story ideas from Johns Hopkins University School of Medicine

NCAA BASKETABLL TOURNAMENT COACHES, REFEREES, PLAYERS AND FANS: IT'S YOUR VOICE! From the first tip-off of March Madness to the championship's final buzzer, thousands of people will relentlessly scream and shout, placing tremendous strain on the voice. While no one is recommending silence, the constant pressure on the vocal chords can cause great damage.

22 Mar 2010

Aastrom Biosciences treats final patient in IMPACT-DCM Phase 2 surgical clinical trial

Aastrom Biosciences, Inc., a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported the final patient treatment in the company's ongoing U.S. Phase 2 surgical clinical trial designated IMPACT-DCM.

10 Mar 2010

USF study: HHV-6 causes permanent infection by inserting its DNA into human chromosomes

Human herpesvirus 6 (HHV-6) infects nearly 100 percent of humans in early childhood, and the infection then lasts for the rest of a person's life. Now, a team led by Peter Medveczky, MD, a professor in the Department of Molecular Medicine at the University of South Florida, has discovered that in some individuals, HHV-6 causes such a permanent infection by inserting or "integrating" its DNA into human chromosomes.

9 Mar 2010

Axiogenesis, Lonza Cologne announce global distribution agreement

Axiogenesis AG has entered into a worldwide, exclusive distribution agreement with Lonza Cologne AG effective 01 January 2010. The agreement includes Axiogenesis’s current product and service portfolio, including the industry standard Cor.At® mouse embryonic stem cell-derived cardiomyocytes.

3 Mar 2010

InterSystems Ensemble platform enables first successful electronic transmission of genetic data

InterSystems Corporation, the global leader in software for connected healthcare, today announced that InterSystems Ensemble® was the software platform for the first-ever successful electronic transmission of comprehensive genetic data. The information was sent cross-country from Boston-based Partners HealthCare Center for Personalized Genetic Medicine (PCPGM) to Intermountain HealthCare in Salt Lake City, Utah. The announcement about reaching this milestone in personalized medicine came at the HIMSS10 conference.

2 Mar 2010

Shire receives FDA Fast Track designation for REPLAGAL

Shire plc, the global specialty biopharmaceutical company, announces it has received Fast Track designation from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease.

24 Feb 2010

Black women are more prone to peripartum cardiomyopathy around childbirth time

A study examining the incidence of peripartum cardiomyopathy in women who gave birth at a Medical College of Georgia's teaching hospital between July 2003 and July 2008, showed that while 55 percent of the women were white, 93 percent of those who developed cardiomyopathy were black, said Dr. Mindy B. Gentry, an MCG cardiologist.

23 Feb 2010

Discharged VAD implanted pediatric patient receives successful heart transplant after eight months

The wait is over for 16-year-old Francesco "Frank" De Santiago. On January 29, De Santiago received a donor heart in a nine-hour transplant operation at Texas Children's Heart Center De Santiago made news last October as the first child ever discharged from a pediatric hospital with an implanted mechanical heart pump, or ventricular assist device (VAD). Until then, pediatric patients with VADs remained in the hospital, often in ICU, while awaiting a donor heart.

15 Feb 2010

Third-quarter fiscal 2010 results announced by Clinical Data

Clinical Data, Inc. (NASDAQ: CLDA) today announced the Company’s operational and financial results for its third fiscal quarter ended December 31, 2009, confirming its plans to submit a new drug application (NDA) for vilazodone for the treatment of depression this quarter.

9 Feb 2010